First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows 92.1% year over year
Q1 FY2026 selling, general & admin of $18.86M rose 92.1% year over year.
Context
- Selling, general & admin increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 39.39M USD
- Year-over-year change
- +37.0%
- 2-year CAGR
- +37.4%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 39.39M | +37.0% |
| FY2024 | 2024-12-31 | 28.76M | +37.8% |
| FY2023 | 2023-12-31 | 20.87M | — |
Selling, General & Admin vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's FY2025 selling, general & admin of $39.39M is the 4th highest of the 10 companies compared; the peer median is $22.58M.
- Its year-over-year change of +37.0% is the 4th highest of 10, against a peer median of +30.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $69.54M | -16.7% | +16.7% | 980.1% | |
| LTM Mar 2026 | $62.81M | +42.2% | +11.5% | 27.0% | |
| LTM Mar 2026 | $46.46M | +34.5% | +22.2% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $39.39M | +37.0% | — | — |
| LTM Mar 2026 | $23.53M | +30.1% | +11.7% | — | |
| LTM Mar 2026 | $22.58M | +5.5% | -4.4% | 269.8% | |
| LTM Jun 2026 | $21.82M | +116.7% | -3.8% | — | |
CLYMClimb Bio, Inc. | LTM Mar 2026 | $21.29M | +7.5% | +3.8% | — |
| LTM Mar 2026 | $16.54M | -15.6% | +10.2% | — | |
| FY2025 | $13.55M | +83.7% | — | 1003.9% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $22.58M | +30.1% | +10.8% | 625.0% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 152.35M | 139.61M |
| Gross Profit | 0 | (152.35M) | (139.61M) |
| Gross Margin | — | — | — |
| Research & Development | 97.59M | 152.35M | 139.61M |
| Selling, General & Admin | 20.87M | 28.76M | 39.39M |
| Operating Expenses | 118.46M | 28.76M | 39.39M |
| Depreciation & Amortization | 2.38M | 2.4M | 559K |
| EBITDA | (116.09M) | (178.7M) | (178.45M) |
| EBITDA Margin | — | — | — |
| Operating Income | (118.46M) | (181.1M) | (179.01M) |
| Operating Margin | — | — | — |
| Interest Income | 12.31M | 17.38M | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 12.31M | 17.4M | 12.92M |
| Income Before Tax | (106.15M) | (163.71M) | (166.09M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (106.15M) | (163.71M) | (166.09M) |
| Net Margin | — | — | — |
| EPS (Basic) | (3.05) | 0.00 | 0.00 |
| EPS (Diluted) | (3.05) | 0.00 | 0.00 |
| Weighted Avg Shares | 34.75M | 0 | 0 |
| Weighted Avg Shares (Diluted) | 34.75M | 0 | 0 |
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.